ID
20217
Descripción
The purpose of this study is to determine the safety and efficacy of natalizumab in the treatment of individuals who have been diagnosed with relapsing remitting multiple sclerosis (MS). It is hoped that natalizumab will prevent certain types of white blood cells from moving out of the bloodstream into organs, including the brain, that are being damaged by autoimmune disease (a disease in which the body's own immune system attacks certain organs). These white blood cells are thought to cause inflammation that can result in lesions (small areas of damage) in the brain. These lesions are thought to be the cause of relapses and disability in MS.
Palabras clave
Versiones (2)
- 30/1/17 30/1/17 -
- 14/2/17 14/2/17 -
Subido en
14 de febrero de 2017
DOI
Para solicitar uno, por favor iniciar sesión.
Licencia
Creative Commons BY-NC 3.0
Comentarios del modelo :
Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.
Comentarios de grupo de elementos para :
Comentarios del elemento para :
Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.
Concomitant Non-Drug Therapy CRFs Multiple Sclerosis Tysabri NCT00027300
Concomitant Non-Drug Therapy CRFs Multiple Sclerosis Tysabri NCT00027300
Similar models
Concomitant Non-Drug Therapy CRFs Multiple Sclerosis Tysabri NCT00027300
C1707479 (UMLS CUI [1,2])
C0087111 (UMLS CUI [1,2])
C0087111 (UMLS CUI [1,2])